Sequenom Posts 27 Percent Q3 Revenue Growth as It Plans FDA Talks on T21 Test

Sequenom's sales rose on increased sales of both MassArray instruments and consumables. The firm said it remains on schedule with development of its trisomy 21 test.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories